Evaluation of efficacy of recombinant Tissue Plasminogen Activator on facility of vitrectomy for diabetic Tractional Retinal Detachment

Evaluation of safety and efficacy of intavitreal injection of recombinant Tissue Plasminogen Activator before vitrectomy for diabetic Tractional Retinal Detachment on facility and outcome of surgery

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200217046522N1

Enrollment

Registered

2020-06-18

Start date

2019-12-22

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Tractional Retinal Detachment. Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula

Interventions

Intervention 1: Intervention group: 19 eyes of 19 patients received intravitreal injections of bevacizumab (2.5 mg/0.1cc) and recombinant tPA (50 µg/0.1cc) at one session, 5-9 days before vitrectomy.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diabetic Tractional Retinal Detachment Candidated for vitrectomy

Exclusion criteria

Exclusion criteria: combined tractional-rhegmatogenous retinal detachment significant media opacity

Design outcomes

Primary

Measure	Time frame
Anatomical success rate. Timepoint: before surgery, one month and three months after surgery. Method of measurement: clinical examination.	—

Secondary

Measure	Time frame
Surgical facility. Timepoint: conclusion of surgery. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKhalil Ghasemi Falavarjani

Iran University of Medical Sciences

ghasemifalavarjani.k@iums.ac.ir+98 21 6655 8811

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026